Skip to main content

Accelerating the Future

Life Sciences and Healthcare Predictions 2030

Our most recent life sciences and healthcare report outlines ten predictions for how the world might look in 2030. It discusses the current evidence shaping our future outlook and examines how AI technologies, particularly GenAI, could accelerate progress towards these predictions.  

While Australians are ranked amongst the healthiest people in the world, we continue to experience challenges around system affordability, equity of access, activity growth and we preform worse than the OECD average on 46% of global quality of care (QoC) indicators.  

We know that a health system that supports all Australians to live their best, healthiest lives requires enhanced consumer experience, personalised medicine, equitable access to high quality care, next generation therapies and smart use of digital and medical technologies.  

The report predicts a significant rise in use of digital health technologies, with telehealth and remote monitoring expected to become standard practice due to increased patient demand and regulatory support.  The intersection of climate change and sustainability with the healthcare sector in Australia is significant, reflecting a growing trend towards environmentally responsible practices and utilisation of Australian biodiversity in pharmaceutical developments.  

Positioning Australia as a leader in medical innovation and fostering public-private partnerships will unlock new economic and social benefits. The report anticipates a shift towards personalised medicine, leveraging genomics and data analytics to tailor treatments to individual patients. Investment in preventive care, care outside the hospital walls will result in better resource allocation. 

With workforce shortages in critical areas like nursing and aged care, there is a significant trend towards more preventive care, aiming to reduce long-term costs and improve health outcomes.  The life sciences sector in Australia is poised for further growth, with increased investment in R&D, particularly in biotech and pharmaceuticals, positioning Australia as a leader in medical innovation.

Overall, there is significant potential for Australia to advance in healthcare through strategic investments, increased R&D and technological adoption. Hear from our eminent global and Australian subject matter experts who provide an optimistic and provocative view of 2030.

Consumers are the CEOs of their own health

Individuals are empowered to manage their own health using data from multiple sources leading to improved health literacy, a reduction in health inequities and personalised insights.
Research
10 minute read

The rise of a dynamic consumer health market

A dynamic Consumer Health (CH) Industry is focused on promoting well-being and extending healthy lifespans. CH companies use genetic, healthcare and behavioural Data to develop personalised, science-based Products and Services. AI-enabled diagnostics, digital tools, wearables, FemTech and AgeTech tools empower self-care. Companies can generate a feedback loop using health Data and real-time Consumer feedback to enable outcome tracking and continuous innovation. Sustainable practices and evidence on commitment to ESG principles help differentiate companies and improve trust. 
Research
10 minute read

Intelligent healthcare and the democratisation of health data

Healthcare is transformed through digital advancements like Virtual care and AI has led to a shift from reactive acute care towards more proactive, personalised care. 
Research
10 minute read

Climate resilience and sustainable healthcare systems

The healthcare and Life Sciences sector recognises its significant role in addressing the climate crisis. While healthcare systems vary in their environmental impact, providers are increasingly prioritising Sustainability and climate resilience through mature ESG strategies. 
Research
10 minute read

The convergence of AI technologies and human expertise in pharma R&D

The biopharma Industry has undergone a Digital Transformation, leveraging AI, automation and patient-centric technologies to significantly accelerate R&D timelines and improve productivity. 
Research
10 minute read

Interdependent innovations in science and technology are reshaping treatment paradigms

Technological and scientific innovations are transforming healthcare delivery. The integration of quantum computing, AI and diverse health Data sources enables precise diagnostics and the development of life-extending therapies. Real-time population health profiles, ethically constructed from this Data, facilitate the identification of disease drivers and the creation of advanced, personalised treatments. These advancements have significantly increased survival rates for some diseases.
Research
10 minute read

The convergence of health, wealth and longevity services

The Future of Health, wealth and longevity Services hinges on a collaborative approach between governments, healthcare providers, health and long-term care insurers, employers and technology companies. This integrated ecosystem will empower individuals to make informed decisions about their health, wealth and longevity.
Research
10 minute read

End-to-end transformation of pharma's commercial activities

Pharma's commercial operations have undergone a complete Digital Transformation, leveraging AI and Data cloud providers and customer relationship management (CRM) providers to streamline processes and shift from a Products-centric to a customer-centric approach. This has led to personalised marketing and support, improved customer experiences and reduced costs.
Research
10 minute read

Realising the potential of the Internet of Medical Things

MedTech companies play an integral part in most patient treatments, with the digital revolution transforming the Industry into a more connected, efficient, agile and customer-centric ecosystem.
Research
10 minute read

Life sciences M&A, divestments and restructuring

Over the past five years, M&An activity has rebounded strongly, driven in part by a step-up in investor activism. M&A has become a critical element in the corporate strategy of every Life Sciences company, helping to unlock growth and innovation and replenish Products Portfolio. Divestments of non-core assets, with operational efficiencies and streamlining Portfolio, freed up capital to invest in new Products, drive growth and help restructure the business.
Research
10 minute read

Get in touch

Justin Scanlan

Health, Human Services and Life Sciences, National Lead Partner
+61 401 500 896